Two stocks in Healthcare
Gerresheimer vs Novartis: profit, growth, debt and price compared
Novartis is stronger on 3 of 6 figures: profit margin, sales growth and debt. Gerresheimer is stronger on 2: price for its expected profit and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GerresheimerGXI.DE | NovartisNOVN.SW | |
|---|---|---|
| Net margin | −17.5% | Stronger: 17.5% |
| Revenue growth, past year | −0.80% | Stronger: +4.70% |
| Debt to equity | 236.7% | Stronger: 128.6% |
| Forward P/E | Stronger: 13.5× | 15.9× |
| Dividend yield | — | 2.78% |
| Analysts | Hold · 12 | Hold · 22 |
| From its 200-day average | Stronger: +13.7% | +9.2% |
Share price over the past year
- Gerresheimer+40.9%
- Novartis+30.9%
20 Nov 202518 Nov 2026
Gerresheimer or Novartis: which is stronger?
- NOVN.SW
Which is more profitable?
Novartis keeps more of each sale as profit: 17.5% against −17.5%.
- NOVN.SW
Which is growing its sales faster?
Novartis is growing its sales faster: +4.70% over the past year, against −0.80%.
- NOVN.SW
Which has borrowed less?
Novartis has borrowed less: its debt is 128.6% of what its shareholders own, against 236.7% for Gerresheimer.
- GXI.DE
Which costs less for the profit it is expected to make?
Gerresheimer costs less for the profit it is expected to make: 13.5× its forward earnings, against 15.9×.
Which pays more in dividends?
Novartis pays 2.78% a year in dividends for what a share costs, where Gerresheimer pays none.
Which do analysts rate higher?
Analysts rate both the same: Hold.
- GXI.DE
Which is in the stronger price trend?
Gerresheimer's price is in the stronger trend: 13.7% above its 200-day average, against 9.2% above.
What each company does
GXI.DEGerresheimer
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally.
Reports results on 25 November 2026
NOVN.SWNovartis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Reports results on 3 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.